Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 8INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 314Lymphoid 41Other hematologic neoplasm 29Thoracic 19Genitourinary 17Gynecologic 7Tumor-Agnostic 5Gastrointestinal 5Breast 4Sarcoma 3Myeloid 3Dermatologic 3Other solid neoplasm 2Head & Neck 2NET 1Endocrine 1CNS 1

Conditions

Melanoma 2Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia 1Glioblastoma 1Carcinoma, Medullary 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cisplatin 15Fluorouracil 14Cyclophosphamide 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Dexamethasone × Dermatologic × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

NCT00629473 2017-11-22

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Celgene

Phase 1 Completed
86 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡